Home > Press > NaturalNano, Inc. Announces Filing of the Form 10K for the Year Ended December 31, 2008
Abstract:
NaturalNano, Inc. (OTC Bulletin Board: NNAN) (FWB: N3N), a developer of extended release technologies and supplier of polymer additives based on naturally occurring nanomaterials, today announced the filing of the Form 10K for the year ended December 31, 2008.
In 2008, The Nano team worked on various development projects with Fortune 500 companies. Fiabila's commercial order, announced April 14, 2009, is a result of our team's development efforts in 2008 and is a validation of our core technology of extended release in consumer products. These technologies are unique to NaturalNano and covered extensively by our patent portfolio. One of our strategic focuses for 2009 is the conversion of our joint development partnership arrangements into commercial orders. We will also be looking for opportunities to license our extensive patent portfolio in product application areas. Our current patent portfolio is displayed on our website (www.naturalnano.com). During 2009, we will be working to strengthen our management and research teams as we continue to seek commercialization opportunities for our unique proprietary technology.
"The recession does not seem to be hindering the high level of company contacts we are continuing to receive," said James Wemett, CEO of NaturalNano. "Companies are paying more attention to our specialized technology of halloysite tubes which are natural occurring, non-toxic, and environmentally friendly and importantly, are not carbon based. There is a growing awareness and interest, across numerous industry applications, of our extensive patent coverage in the extended time release area."
####
About NaturalNano, Inc.
Headquartered in Rochester, NY, NaturalNano, Inc. (OTCBB: NNAN) (FWB: N3N) develops and commercializes products and solutions for extended release attributes for consumer goods as well as polymer additives based on naturally occurring nanomaterials from halloysite. The Company offers its proprietary Pleximer(TM) line of additives for industrial polymers, plastics and composites. NaturalNano holds and licenses more than 25 patents and its applications, as well as proprietary know-how for extraction, classification, and modification of non-toxic and environmentally friendly halloysite natural tubules (HNT).
Cautionary Statement Regarding Forward-Looking Statements: This press release may contain forward-looking statements regarding future events and future performance of NaturalNano that involve risks and uncertainties that could materially affect actual results. This information is qualified in its entirety by cautionary statements and risk factors disclosure contained in certain of NaturalNano’s filings with the Securities and Exchange Commission. The most recent annual reports on Form 10-KSB and quarterly reports on Form 10-QSB filed by NaturalNano provide information about these factors, which may be revised or supplemented in future reports to the SEC on those forms or on Form 8-K. We caution investors not to place undue reliance on forward-looking statements, and we do not undertake any obligation to update or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other such factors that affect the subject of these statements, except where expressly required by law.
For more information, please click here
Copyright © PR Newswire Association LLC.
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Materials/Metamaterials/Magnetoresistance
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Focused ion beam technology: A single tool for a wide range of applications January 12th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||